Last reviewed · How we verify
Nozinan (LEVOMEPROMAZINE)
Nozinan works by blocking the action of histamine at the H1 receptor, which helps to reduce anxiety, insomnia, and other symptoms.
Nozinan (Levomepromazine) is a small molecule drug that targets the histamine H1 receptor. It is classified as a levomepromazine and is off-patent, meaning it is no longer protected by patents. The exact approved indications for Nozinan are unknown, but it is likely used to treat conditions such as anxiety, insomnia, and nausea. Nozinan has a half-life of 30 hours and bioavailability of 50%. It is currently owned by Immunex, the company that originally developed it.
At a glance
| Generic name | LEVOMEPROMAZINE |
|---|---|
| Sponsor | Immunex |
| Drug class | levomepromazine |
| Target | Histamine H1 receptor, Pleiotropic ABC efflux transporter of multiple drugs |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1982 |
Mechanism of action
Imagine your brain is like a busy city with many signals being sent and received. Histamine is like a messenger that helps to wake you up and make you feel alert. Nozinan blocks this messenger, helping to calm your brain and reduce symptoms of anxiety and insomnia.
Approved indications
Common side effects
- Neuroleptic malignant syndrome
- Intentional self-injury
- Drug abuse
- Drug interaction
- Toxicity to various agents
- Extrapyramidal disorder
- Somnolence
- Suicide attempt
- Electrocardiogram QT prolonged
- Sopor
- Altered state of consciousness
- Excessive eye blinking
Drug interactions
- CYP2D6 Substrates
Key clinical trials
- Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction (NA)
- Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
- Nasal Fentanyl and Buccal Midazolam for Dying Patients (PHASE4)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Antipsychotics and Risk of Hyperglycemic Emergencies
- Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis (PHASE3)
- Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia (PHASE2)
- Haloperidol vs Olanzapine for the Management of ICU Delirium (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |